APA (7th ed.) Citation

Dri, A., Foffano, L., Molteni, E., Franzoni, A., Lay, L., Cucciniello, L., . . . Puglisi, F. (2024). 416P Prognostic impact of liquid biopsy (LB) biomarkers at relapse on second-line (2L) treatment (Tx) after progression to endocrine therapy (ET) in metastatic breast cancer (mBC): Ancillary analysis of the MAGNETIC.1 study. Annals of Oncology, 35, S395. https://doi.org/10.1016/j.annonc.2024.08.364

Chicago Style (17th ed.) Citation

Dri, A., et al. "416P Prognostic Impact of Liquid Biopsy (LB) Biomarkers at Relapse on Second-line (2L) Treatment (Tx) After Progression to Endocrine Therapy (ET) in Metastatic Breast Cancer (mBC): Ancillary Analysis of the MAGNETIC.1 Study." Annals of Oncology 35 (2024): S395. https://doi.org/10.1016/j.annonc.2024.08.364.

MLA (9th ed.) Citation

Dri, A., et al. "416P Prognostic Impact of Liquid Biopsy (LB) Biomarkers at Relapse on Second-line (2L) Treatment (Tx) After Progression to Endocrine Therapy (ET) in Metastatic Breast Cancer (mBC): Ancillary Analysis of the MAGNETIC.1 Study." Annals of Oncology, vol. 35, 2024, p. S395, https://doi.org/10.1016/j.annonc.2024.08.364.